Q Line Biotech IPO GMP Today, Price & Details
Q Line Biotech IPO GMP Today, Price Band, Subscription Status, Allotment & Listing Details
About Q Line Biotech
Q Line Biotech is stepping into the public market via the NSE SME platform, aiming to raise substantial capital for its growth initiatives. The company operates within a dynamic sector, and its IPO structure is noteworthy for being entirely a fresh issue, indicating a focus on expanding its operational capacity rather than facilitating an exit for existing shareholders. This approach often signals confidence in future performance and a clear plan for utilizing the raised funds to fuel expansion.
Financially, Q Line Biotech has demonstrated a robust performance in its recent reporting period. With revenues touching ₹232.42 Cr and a Profit After Tax (PAT) of ₹38.69 Cr, the company shows a healthy operational scale. The Earnings Per Share (EPS) stands at a respectable ₹28.63. The IPO is structured as a pure fresh issue of ₹214.48 Cr, meaning all proceeds will go directly into the company's coffers to fund its ambitious plans. There is no Offer for Sale (OFS) component, which is a positive sign for fresh capital infusion.
The company's competitive positioning is underpinned by its financial metrics, including a strong Return on Net Worth (RONW) of 23.74% and a Return on Capital Employed (ROCE) of 17.66%. The EBITDA margin is also healthy at 22.73%, suggesting efficient operations. The Net Asset Value (NAV) per share stands at ₹120.6. The funds raised from this IPO are earmarked for significant expansion activities, which are crucial for maintaining its growth trajectory and strengthening its market standing in a competitive landscape. This fresh capital infusion is expected to bolster its infrastructure and operational capabilities.
Q Line Biotech IPO — Investment Analysis
Q Line Biotech's IPO is priced at ₹326 per share, with a face value of ₹10. The company has reported an EPS of ₹28.63, which translates to a P/E ratio of 11.4x based on the upper end of the price band. This valuation appears to be in a reasonable zone when compared to industry averages, especially considering the company's profitability. It suggests that the issue is not excessively priced, offering potential value to investors if the company can sustain its growth. The fixed price band at ₹326 simplifies the pricing for investors, removing the typical band volatility.
Financially, Q Line Biotech presents a compelling picture. Its revenue stood at ₹232.42 Cr, and it achieved a PAT of ₹38.69 Cr, reflecting healthy profitability. The EBITDA margin of 22.73% is a strong indicator of operational efficiency. Furthermore, the company boasts a commendable RONW of 23.74% and a ROCE of 17.66%, showcasing its ability to generate good returns on shareholder equity and capital employed respectively. These metrics suggest a well-managed business with a solid financial foundation.
The IPO's growth outlook is tied to the effective deployment of the fresh issue proceeds, which are intended for expansion. However, like all SME IPOs, there are inherent risks. The company's reliance on future growth and market acceptance of its expanded operations is a key factor. Additionally, the SME platform itself carries higher volatility and liquidity risks compared to mainboard listings. The fact that it's a pure fresh issue means no exit for existing investors, which can be seen positively, but also means the entire capital raised is dependent on future performance. Sector-specific risks and competitive pressures also need careful consideration.
The subscription levels for Q Line Biotech's IPO will be a critical indicator of market sentiment. Strong subscription from Qualified Institutional Buyers (QIBs) and High Net-worth Individuals (HNIs) would signal institutional confidence, while robust retail participation would highlight broader investor interest. Given its SME status, we'll be watching how both segments react. The grey market premium (GMP), if available, can also provide a preliminary indication of investor demand, though it's an unofficial metric. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.
Q Line Biotech IPO — Pros & Cons
Strengths
- The company has reported a strong Profit After Tax (PAT) of ₹38.69 Cr on revenues of ₹232.42 Cr, indicating robust profitability. This healthy profit generation capability is a positive sign for investors looking for financially sound businesses.
- Q Line Biotech demonstrates excellent returns on shareholder funds with a RONW of 23.74%, which is quite impressive. This high return suggests efficient utilization of equity capital to generate profits, a key factor for long-term investor value.
- The company's operational efficiency is highlighted by its solid EBITDA margin of 22.73%, which is a strong indicator of its ability to manage costs effectively. A high EBITDA margin contributes positively to the bottom line and operational health.
- The IPO is a pure fresh issue of ₹214.48 Cr, meaning all funds will be infused into the company for expansion. This capital infusion is expected to fuel future growth and business development, which is beneficial for the company's long-term prospects.
- The P/E ratio of 11.4x, based on an EPS of ₹28.63, appears to be attractively valued in the current market. This valuation suggests that investors can potentially acquire a stake in a profitable company at a reasonable price point, offering room for appreciation.
Risks
- As an SME IPO, Q Line Biotech is subject to higher volatility and potentially lower liquidity compared to mainboard listings. This means investors might find it harder to exit their positions quickly at desired prices, posing a risk to capital preservation.
- The company's growth trajectory heavily relies on the successful deployment of the IPO proceeds for expansion. Any delays or inefficiencies in utilizing the raised capital could hinder its ability to meet growth expectations, impacting investor returns.
- While the financial performance is strong, the competitive landscape within its sector could pose challenges. New entrants or aggressive strategies by existing players might put pressure on Q Line Biotech's market share and profitability.
- Information regarding the company's debt levels and cash flow from operations is not detailed in the provided data. A deeper understanding of its financial leverage and liquidity management would be beneficial for a comprehensive risk assessment.
- The Net Asset Value (NAV) per share stands at ₹120.6, while the issue price is ₹326. This implies investors are paying a premium over the book value, which is common for growth companies but warrants careful consideration of future earnings potential.
Q Line Biotech IPO Details
| Company Name | Q Line Biotech |
|---|---|
| IPO Type | SME |
| Exchange | NSE |
| Price Band | ₹326 - ₹343 |
| Face Value | ₹10 per share |
| Lot Size | 400 shares |
| Min Investment | ₹137,200 |
| Total Issue Size | ₹214.48 Cr |
|---|---|
| Fresh Issue | ₹214.48 Cr |
| Registrar | Purva Sharegistry (India) Pvt.Ltd. |
| Lead Manager | List of Issues managed, Hem Securities Ltd., Share India Capital Services Pvt.Ltd. |
| IPO Status | Listed |
Q Line Biotech IPO Dates
Q Line Biotech IPO Subscription Status
Day-wise Subscription Trend
| Date | Retail | NII/HNI | QIB | Total |
|---|---|---|---|---|
| 25 May 2026 | 71.44x | 146.33x | 123.94x | 102.49x |
| 22 May 2026 | 9.92x | 15.96x | 5.19x | 9.86x |
| 21 May 2026 | 3.61x | 5.24x | 4.15x | 4.11x |
Q Line Biotech IPO Listing Performance
Q Line Biotech IPO listed on NSE on 29 May 2026 at ₹452, a premium of 31.8% over the issue price of ₹343. Investors who received allotment made a profit of ₹43,600 per lot (400 shares) on listing day.
Q Line Biotech IPO — Key Highlights
- The company reported a robust PAT of ₹38.69 Cr, showcasing strong profitability.
- Q Line Biotech boasts an impressive RONW of 23.74%, indicating efficient use of shareholder equity.
- The IPO is a pure fresh issue of ₹214.48 Cr, dedicated entirely to business expansion.
- An EPS of ₹28.63 results in an attractive P/E ratio of 11.4x.
- The EBITDA margin stands at a healthy 22.73%, signaling good operational efficiency.
- The Net Asset Value (NAV) per share is ₹120.6, providing a book value benchmark.
Q Line Biotech Financial Performance
| Metric (₹ Cr) | FY 2023 | FY 2024 | FY 2025 | 9M FY 2026 |
|---|---|---|---|---|
| Revenue | 182.74 | 203.65 | 313.78 | 232.42 |
| Expenses | 154.97 | 175.85 | 261.43 | 186.96 |
| Net Income (PAT) | 32.10 | 34.44 | 28.13 | 38.69 |
| Margin (%) | 17.57% | 16.91% | 8.96% | 16.65% |
Q Line Biotech IPO Valuations & Key Metrics
Valuation Ratios
| EPS | ₹28.63 |
|---|---|
| P/E Ratio | 11.40x |
| NAV | ₹120.60 |
| Current Ratio | 1.48 |
| Debt/Equity | 0.870 |
Return Metrics
| RONW (%) | 23.74% |
|---|---|
| ROCE (%) | 17.66% |
| EBITDA Margin | 22.73% |
Q Line Biotech IPO Reservation / Allocation
Q Line Biotech IPO Anchor Investors
| Bid Date | 20 May 2026 |
|---|---|
| Shares Offered | 17,81,200 shares |
| Anchor Portion (INR Cr.) | INR 61.10 crore |
| Anchor lock-in period end date for 50% shares (30 Days) | 22 June 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | 20 August 2026 |
Q Line Biotech IPO Lead Manager & Registrar
Book Running Lead Manager
List of Issues managed, Hem Securities Ltd., Share India Capital Services Pvt.Ltd.
IPO Registrar
Purva Sharegistry (India) Pvt.Ltd.
Q Line Biotech IPO — Frequently Asked Questions
What is Q Line Biotech IPO GMP today?
As of today, the Grey Market Premium (GMP) for Q Line Biotech IPO is ₹115 per share, indicating a potential listing premium of 33.5% above the issue price of ₹343.
What is the price band and lot size of Q Line Biotech IPO?
Q Line Biotech IPO has a price band of ₹326 to ₹343 per equity share with a face value of ₹10. The minimum lot size is 400 shares, requiring a minimum investment of ₹137,200 at the upper band.
What are the important dates for Q Line Biotech IPO?
Q Line Biotech IPO opens for subscription on 21 May 2026 and closes on 25 May 2026. Allotment is expected on 26 May 2026. The shares are expected to list on NSE on 29 May 2026.
What is the investor category allocation in Q Line Biotech IPO?
The shares are reserved as follows — Qualified Institutional Buyers (QIB): 49.99%, Non-Institutional Investors (NII/HNI): 15.01%, and Retail Individual Investors: 35.00%.
How can I apply for Q Line Biotech IPO?
You can apply for Q Line Biotech IPO through your bank's net banking ASBA facility or via UPI-based application through any stockbroker platform. Ensure you have sufficient funds in your bank account as the amount will be blocked until allotment. The registrar for this IPO is Purva Sharegistry (India) Pvt.Ltd..
What is the subscription status of Q Line Biotech IPO?
Q Line Biotech IPO has been subscribed 102.49 times overall. Retail category: 71.44x, NII/HNI: 146.33x, QIB: 123.94x.
What is Q Line Biotech IPO price band and lot size?
The Q Line Biotech IPO is offered at a fixed price of ₹326 per share. The lot size for this IPO is 400 shares, meaning the minimum investment required is ₹130,400 (400 shares x ₹326). The face value of each share is ₹10.
Is Q Line Biotech IPO worth investing in?
Q Line Biotech presents a mixed bag for potential investors. On the positive side, it has strong financial metrics, including a good PAT of ₹38.69 Cr and an impressive RONW of 23.74%. The P/E of 11.4x also appears reasonable.
However, it's crucial to weigh these strengths against the inherent risks of an SME IPO, such as higher volatility and potential liquidity concerns. The reliance on future growth funded by the IPO proceeds is also a key factor. Investors should carefully consider their risk appetite and investment horizon. This is informational analysis based on available data, not investment advice.
What is Q Line Biotech IPO GMP today?
Grey Market Premium (GMP) for the Q Line Biotech IPO is an unofficial indicator of market sentiment and is subject to change. While specific GMP figures are not provided here, it's important to note that GMP reflects the demand for the IPO in the unofficial market. Investors should treat GMP with caution, as it's not a guaranteed indicator of listing performance and should not be the sole basis for investment decisions.
How to apply for Q Line Biotech IPO?
You can apply for the Q Line Biotech IPO through two primary methods: UPI or ASBA (Application Supported by Blocked Amount). For UPI, you'll need a UPI ID and will authorize the bid through your banking app. With ASBA, you can apply through your bank's net banking or by submitting a physical form, where funds are blocked in your account until allotment.
The specific registrar for this IPO would facilitate the application process.